Vascular Solutions Announces Re-Launch of Venture(R) Catheter

Vascular Solutions Announces Re-Launch of Venture(R) Catheter

-  Catheter previously offered by St. Jude Medical is once again

- Venture catheter provides precision guidewire placement in complex
interventions, with over seven years of clinical use

- Available in rapid-exchange, over-the-wire, and coronary sinus access

MINNEAPOLIS, April 29, 2013 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc.
(Nasdaq:VASC) today announced that it has re-launched the Venture catheter, a
deflectable-tip catheter used to provide guidewire directional control in
challenging coronary and peripheral interventional procedures. The device is
available immediately in the United States and expected to become available in
select international markets over the next few months.

The Venture catheter's deflectable atraumatic distal tip can be angled up to
90 degrees, providing physicians with control and precision while navigating
complex turns in the vessel and lending back-up support when crossing tight
lesions. The Venture catheter is available in three versions: rapid-exchange
(RX) and over-the-wire (OTW) models for difficult coronary and peripheral
cases and a specialized coronary sinus version for directing wires in
left-ventricular lead placement in bi-ventricular implantable defibrillator
procedures. All three versions are 6 French guide-compatible and are used with
standard 0.014-inch guidewires.

As previously announced, Vascular Solutions acquired the Venture catheter from
St. Jude Medical, Inc. in August of 2012. Since the acquisition, Vascular
Solutions sold the remaining limited inventory and completed the installation
and validation of the Venture production equipment and processes in its
manufacturing facility.While the catheter was in full commercialization under
St. Jude Medical, the Venture catheter was generating $3 million in annual
worldwide sales, including approximately $2 million in U.S. sales. Vascular
Solutions intends to rebuild sales gradually to those levels, with the
expected sales ramp already incorporated into the company's financial guidance
for 2013.

"During more than seven years on the market, the Venture catheter has amassed
a very impressive record of clinical utility in some of the most challenging
interventional cases," said Howard Root, Chief Executive Officer of Vascular
Solutions. "The Venture catheter is an indispensible tool for physicians who
perform complex interventions, and we are very pleased to once again make this
catheter available. We believe the clinical community will welcome the return
of the Venture catheter to the market as we see a significant amount of
initial pent-up demand for this one-of-a-kind device."

"The acquisition of the Venture catheter is consistent with our strategy of
pursuing tuck-in acquisitions that leverage our existing distribution network
and established call points," Mr. Root added. "The addition of the Venture
catheter also is part of our commitment to offering clinical solutions in
complex interventions, such as we have done with our internally-developed
GuideLiner® guide extension device and SuperCross™ microcatheters."

The Venture catheter is indicated for directing, steering, controlling, and
supporting a guidewire to access discrete regions of the coronary and
peripheral vasculature. The over-the-wire versions may also be used for manual
delivery of saline solution or diagnostic contrast agents.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses
on developing unique clinical solutions for coronary and peripheral vascular
procedures.The company's product line consists of over 70 products in three
categories: catheter products, hemostat products and vein products.Vascular
Solutions delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein specialists
through its direct U.S. sales force and international independent distributor

The information in this press release contains forward-looking statements,
including statements regarding the international availability of the Venture
catheter and expectations about the product's sales, that involve risks and
uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements. Important factors that may
cause such differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2012 and other recent filings with the
Securities and Exchange Commission. The risks and uncertainties include,
without limitation, risks associated with the need for adoption of our new
products, lack of sustained profitability, exposure to intellectual property
claims, significant variability in quarterly results, exposure to possible
product liability claims, the development of new products by others, doing
business in international markets, the availability of third party
reimbursement, and actions by the FDA.

For further information, connect to

CONTACT: James Hennen, CFO
         Phil Nalbone, VP
         Vascular Solutions, Inc.
         (763) 656-4300
Press spacebar to pause and continue. Press esc to stop.